Deutsche Bank AG acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 938,919 shares of the company's stock, valued at approximately $14,919,000. Deutsche Bank AG owned about 2.75% of NeuroPace as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Light Asset Management LLC raised its stake in NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company's stock valued at $32,349,000 after acquiring an additional 1,110,484 shares during the period. Kotler Kevin bought a new position in NeuroPace during the fourth quarter worth $9,750,000. Walleye Capital LLC increased its holdings in shares of NeuroPace by 344.6% in the fourth quarter. Walleye Capital LLC now owns 228,847 shares of the company's stock valued at $3,533,000 after purchasing an additional 177,375 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of NeuroPace by 44.6% in the second quarter. Geode Capital Management LLC now owns 485,162 shares of the company's stock valued at $5,406,000 after purchasing an additional 149,595 shares during the last quarter. Finally, Armistice Capital LLC raised its position in shares of NeuroPace by 12.6% in the third quarter. Armistice Capital LLC now owns 1,298,000 shares of the company's stock valued at $13,382,000 after purchasing an additional 145,665 shares during the period. 78.83% of the stock is currently owned by institutional investors.
NeuroPace Trading Up 0.1%
NPCE stock opened at $14.03 on Friday. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94. The company's 50-day simple moving average is $15.34 and its 200 day simple moving average is $15.32. NeuroPace, Inc. has a 52 week low of $8.61 and a 52 week high of $19.60. The company has a market capitalization of $481.51 million, a PE ratio of -24.61 and a beta of 1.92.
NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. The business had revenue of $22.83 million during the quarter, compared to analysts' expectations of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. As a group, sell-side analysts anticipate that NeuroPace, Inc. will post -0.67 earnings per share for the current year.
Wall Street Analysts Forecast Growth
NPCE has been the subject of a number of research reports. Guggenheim restated a "neutral" rating on shares of NeuroPace in a research note on Wednesday, July 29th. Cantor Fitzgerald reissued an "overweight" rating on shares of NeuroPace in a report on Monday, August 17th. Weiss Ratings restated a "sell (d-)" rating on shares of NeuroPace in a research report on Wednesday, June 24th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of NeuroPace in a report on Wednesday, July 29th. Finally, Mizuho started coverage on NeuroPace in a report on Thursday, July 23rd. They set an "outperform" rating and a $22.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, NeuroPace currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.29.
Check Out Our Latest Report on NPCE
About NeuroPace
(
Free Report)
NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company's mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.
The company's flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.
See Also
Want to see what other hedge funds are holding NPCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroPace, Inc. (NASDAQ:NPCE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
